Update shared on 07 Nov 2025
Analysts have revised their price target for 4DMedical to $1.82 per share, maintaining the previous valuation. Cautious adjustments to profit margin forecasts were offset by sustained robust revenue growth expectations.
What's in the News
- 4DMedical Limited (ASX:4DX) was dropped from the S&P/ASX All Ordinaries Index (Key Developments).
- 4DMedical announced U.S. Food and Drug Administration (FDA) 510(k) clearance for CT:VQ, the world's first and only non-contrast, ventilation-perfusion imaging solution (Key Developments).
- The U.S. Centers for Medicare & Medicaid Services (CMS) confirmed reimbursement for CT:VQ under Category III CPT codes, in addition to existing chest CT reimbursement (Key Developments).
- CT:VQ software enables routine non-contrast chest CTs to be converted into quantitative ventilation and perfusion maps for enhanced lung imaging. This facilitates expanded access at hospitals and imaging centers that do not have nuclear medicine capabilities (Key Developments).
- Early U.S. clinical partners for CT:VQ have included Stanford University and Brooke Army Medical Center. Initial findings were presented at the 2025 American Thoracic Society meeting (Key Developments).
Valuation Changes
- Consensus Analyst Price Target: Remains unchanged at A$1.82 per share.
- Discount Rate: Increased slightly from 7.49% to 7.79%.
- Revenue Growth: Marginally decreased from 115.91% to 115.18%.
- Net Profit Margin: Fell significantly from 17.44% to 4.56%.
- Future P/E: Increased sharply from 132.6x to 516.6x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.